Ultragenyx Q2 revenue $214M, net loss narrows to $0.90/share; reaffirms 2026 guidance

Ultragenyx Pharmaceutical Inc.

Q2 total revenue $214M (up 28% YoY); Crysvita $156M, Dojolvi $27M, Evkeeza $21M, Mepsevii $10M.
Net loss $92M ($0.90/share) vs $115M ($1.17) in Q2 2025; operating expenses $289M.
Reaffirms FY2026 revenue guidance $730M-$760M; combined R&D/SG&A flat to slightly down vs 2025; on track for profitability in 2027.
Upcoming catalysts: PDUFA for DTX401 (Aug 23) and UX111 (Sep 19); GTX-102 Phase 3 data in Sep/Oct 2026.
Cash $436M; net cash used in operations $97M in Q2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.